Analysed PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ) News Sources
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
17-12-2025
yahoo.com
Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
18-12-2025
yahoo.com
Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
26-12-2025
yahoo.com
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
05-01-2026
yahoo.com
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09-01-2026
yahoo.com
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
12-01-2026
yahoo.com
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
29-07-2026
yahoo.com
What is the current price of PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ)?
The current price of PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ) is $2.13.
PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ) absolute price change since previous trading day?
The absolute price change of PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ) since the previous trading day is $-0.05.
PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ) percentage price change since previous trading day?
The percentage price change of PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ) since the previous trading day is -2.2936%.
What is the most recent average sentiment score for PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ)?
The most recent average sentiment score for PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ)?
The most recent sentiment for PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ) is .
SEC-8K** Filing Available For PROCESSA PHARMACEUTICALS INC (PCSA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.